Ivermoh-S 12 Tablet contains Ivermectin 12 mg, an antiparasitic agent effective against a broad spectrum of parasitic infections. Ivermectin works by binding selectively to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates, leading to increased permeability to chloride ions, hyperpolarization, paralysis, and death of the parasite. It is commonly indicated for the treatment of strongyloidiasis, onchocerciasis, and other parasitic infestations such as scabies and lice. Ivermoh-S 12 is administered orally, with dosage and duration tailored according to the specific parasitic infection and patient’s weight and clinical condition. It is generally well tolerated; however, adverse effects may include dizziness, pruritus, nausea, diarrhea, and mild transient elevations in liver enzymes. Caution is advised in patients with impaired liver function, and it is contraindicated in individuals with known hypersensitivity to Ivermectin or any tablet components. Use during pregnancy and lactation should be under strict medical supervision. Ivermoh-S 12 Tablet should be used as prescribed by a healthcare professional, ensuring adherence to recommended dosing to maximize efficacy and minimize resistance development. Regular monitoring and follow-up are essential to assess therapeutic response and detect any potential adverse reactions.